Maximilian Haist, Henner Stege, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Friedegund Meier, Peter Mohr, Katharina C Kähler, Michael Weichenthal, Axel Hauschild, Dirk Schadendorf, Selma Ugurel, Georg Lodde, Lisa Zimmer, Ralf Gutzmer, Dirk Debus, Bastian Schilling, Alexander Kreuter, Jens Ulrich, Frank Meiss, Rudolf Herbst, Andrea Forschner, Ulrike Leiter, Claudia Pfoehler, Martin Kaatz, Fabian Ziller, Jessica C Hassel, Michael Tronnier, Michael Sachse, Edgar Dippel, Patrick Terheyden, Carola Berking, Markus V Heppt, Felix Kiecker, Sebastian Haferkamp, Christoffer Gebhardt, Jan Christoph Simon, Stephan Grabbe, Carmen Loquai
BACKGROUND: Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improves recurrence-free survival (RFS) for patients with advanced, BRAF V600-mutant ( BRAF mut) resected melanoma. However, 40% of these patients will develop distant metastases (DM) within 5 years, which require systemic therapy. Little data exist to guide the choice of upfront adjuvant therapy or treatment management upon DM. This study evaluated the efficacy of subsequent treatments following tumor recurrence upon upfront adjuvant therapy...
September 2023: Journal for Immunotherapy of Cancer